This 2016 Phase II clinical trial assessed the efficacy of bipolar androgen therapy (BAT) in 33 men with androgen ablation-naïve prostate cancer. Following a 6-month androgen deprivation therapy (ADT) lead-in, patients received alternating cycles of BAT and ADT. The primary endpoint, defined as a prostate-specific antigen (PSA) level
